Celebrex information disclosure
FDA must release to Public Citizen's Health Research Group the raw patient data in Searle's Celebrex advisory committee packet, following a Jan. 19 summary judgement by Washington D.C. federal court Judge James Robertson that the information is not covered by Freedom of Information Act exemptions. HRG's request for release of names of Searle's scientific investigators and titles of unpublished articles by Searle investigators submitted to FDA was denied. Public disclosure of advisory committee materials was mandated under a July settlement with HRG, though the agency may redact material it considers confidential (1"The Pink Sheet" Jan. 3, p. 21)
You may also be interested in...
A drug receiving six-month priority review could have its review time extended by up to two months if its sponsor requests redaction of the advisory committee package, FDA said in a draft guidance.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials